YD Bio (NASDAQ:YDES) Rating Increased to Hold at Wall Street Zen

YD Bio (NASDAQ:YDES) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Separately, Weiss Ratings reiterated a “sell (d+)” rating on shares of YD Bio in a report on Monday, December 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

YD Bio Trading Down 5.0%

NASDAQ YDES opened at $8.58 on Friday. YD Bio has a 12 month low of $7.20 and a 12 month high of $25.00. The company’s 50 day moving average is $11.05.

Institutional Investors Weigh In On YD Bio

An institutional investor recently raised its position in YD Bio stock. Geode Capital Management LLC boosted its position in YD Bio Limited (NASDAQ:YDES) by 10.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 58,363 shares of the biotechnology company’s stock after buying an additional 5,292 shares during the quarter. Geode Capital Management LLC owned approximately 0.08% of YD Bio worth $711,000 at the end of the most recent reporting period.

YD Bio Company Profile

YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.